| Literature DB >> 2882180 |
R E Clark, A Jacobs, C J Lush, S A Smith.
Abstract
A randomised therapeutic trial of 13-cis-retinoic acid was carried out in 70 patients with myelodysplastic syndrome having 5% or fewer marrow blast cells. Among non-sideroblastic patients the 1-year survival in the treated group was 77%, compared with 36% in the control group. There were too few deaths among patients with sideroblastic anaemia to allow any effect of therapy on survival to be evaluated.Entities:
Mesh：
Substances：
Year: 1987 PMID： 2882180 DOI： 10.1016/s0140-6736(87)92796-6
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321